NasdaqGM - Delayed Quote USD
Mural Oncology plc (MURA)
At close: November 21 at 4:00 PM EST
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 2 | 3 | 3 |
| Avg. Estimate | -1.98 | -1.96 | -7.54 | -4.72 |
| Low Estimate | -2.03 | -2.05 | -7.59 | -5.32 |
| High Estimate | -1.95 | -1.86 | -7.51 | -3.9 |
| Year Ago EPS | -- | -1.84 | -- | -7.54 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | 0.00% |
Earnings History
| CURRENCY IN USD | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|
| EPS Est. | -2.66 | -1.9 | -1.96 |
| EPS Actual | -1.84 | -1.86 | -1.87 |
| Difference | 0.82 | 0.04 | 0.09 |
| Surprise % | 30.83% | 2.11% | 4.59% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.98 | -1.96 | -7.54 | -4.72 |
| 7 Days Ago | -2.01 | -1.96 | -7.59 | -5.07 |
| 30 Days Ago | -1.97 | -1.79 | -7.47 | -4.35 |
| 60 Days Ago | -2.14 | 0 | -7.54 | -3.94 |
| 90 Days Ago | -2.14 | 0 | -7.54 | -3.94 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 1 | 1 |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | MURA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 5.00% |
| Next Qtr. | -6.25% | -- | -- | 12.00% |
| Current Year | -- | -- | -- | 2.10% |
| Next Year | 37.47% | -- | -- | 12.20% |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/14/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/11/2024 |
| Initiated | HC Wainwright & Co.: Buy | 10/17/2024 |
| Initiated | Raymond James: Strong Buy | 10/4/2024 |
| Initiated | Rodman & Renshaw: Buy | 6/28/2024 |
| Initiated | Morgan Stanley: Overweight | 4/4/2024 |
Related Tickers
XLO Xilio Therapeutics, Inc.
0.9200
-2.25%
BRNS Barinthus Biotherapeutics plc
0.9882
+9.92%
EDSA Edesa Biotech, Inc.
2.1100
-4.09%
FRTX Fresh Tracks Therapeutics, Inc.
0.7200
+0.70%
ZURA Zura Bio Limited
2.9300
+1.03%
BOLD Boundless Bio, Inc.
2.5700
-5.17%
KRON Kronos Bio, Inc.
0.8743
+1.66%
NUVL Nuvalent, Inc.
92.73
+1.71%
GYRE Gyre Therapeutics, Inc.
11.75
-8.99%
ELDN Eledon Pharmaceuticals, Inc.
4.0700
+5.71%